Chemical and Systems Biology, Chem-H, Stanford Cancer Institute, Stanford Medicine, Stanford University, Stanford, CA, USA.
Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Eur J Med Chem. 2023 Feb 5;247:115027. doi: 10.1016/j.ejmech.2022.115027. Epub 2022 Dec 24.
Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks), a family of three members in mammals (α, β and γ), have emerged as potential therapeutic targets due to their role in regulating many important cellular signaling pathways. In comparison to the PI5P4Kα and PI5P4Kβ, which usually have similar expression profiles across cancer cells, PI5P4Kγ exhibits distinct expression patterns, and pathological functions for PI5P4Kγ have been proposed in the context of cancer and neurodegenerative diseases. PI5P4Kγ has very low kinase activity and has been proposed to inhibit the PI4P5Ks through scaffolding function, providing a rationale for developing a selective PI5P4Kγ degrader. Here, we report the development and characterization of JWZ-1-80, a first-in-class PI5P4Kγ degrader. JWZ-1-80 potently degrades PI5P4Kγ via the ubiquitin-proteasome system and exhibits proteome-wide selectivity and is therefore a useful tool compound for further dissecting the biological functions of PI5P4Kγ.
磷脂酰肌醇 5-磷酸 4-激酶(PI5P4Ks)是哺乳动物中具有三个成员(α、β 和 γ)的家族,由于其在调节许多重要细胞信号通路中的作用,已成为潜在的治疗靶点。与通常在癌细胞中具有相似表达谱的 PI5P4Kα 和 PI5P4Kβ 相比,PI5P4Kγ 表现出不同的表达模式,并且已经提出了 PI5P4Kγ 在癌症和神经退行性疾病中的病理功能。PI5P4Kγ 的激酶活性非常低,并且已经通过支架功能被提议抑制 PI4P5Ks,为开发选择性 PI5P4Kγ 降解剂提供了依据。在这里,我们报告了第一类 PI5P4Kγ 降解剂 JWZ-1-80 的开发和表征。JWZ-1-80 通过泛素-蛋白酶体系统有效地降解 PI5P4Kγ,表现出全蛋白质组选择性,因此是进一步剖析 PI5P4Kγ 生物学功能的有用工具化合物。